Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Leases (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Current Leases readings, the most recent being $145000.0 for Q4 2025.

  • On a quarterly basis, Current Leases rose 302.78% to $145000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $145000.0, a 302.78% increase, with the full-year FY2025 number at $145000.0, up 302.78% from a year prior.
  • Current Leases hit $145000.0 in Q4 2025 for Aligos Therapeutics, up from $21000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.5 million in Q2 2025 to a low of $4000.0 in Q2 2024.
  • Median Current Leases over the past 5 years was $138000.0 (2021), compared with a mean of $1.3 million.
  • Biggest five-year swings in Current Leases: crashed 99.87% in 2024 and later soared 87450.0% in 2025.
  • Aligos Therapeutics' Current Leases stood at $138000.0 in 2021, then soared by 2099.28% to $3.0 million in 2022, then plummeted by 99.67% to $10000.0 in 2023, then skyrocketed by 260.0% to $36000.0 in 2024, then surged by 302.78% to $145000.0 in 2025.
  • The last three reported values for Current Leases were $145000.0 (Q4 2025), $21000.0 (Q3 2025), and $3.5 million (Q2 2025) per Business Quant data.